Newsmeme!
Discover News you didn't know existed
SAN DIEGO----Ligand Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration has granted accelerated approval of GlaxoSmithKline’s PROMACTA® for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
No tags found at this time. Be the first to tag this news item, learn more.
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA ... - Earthtimes
SAN DIEGO - (Business Wire) Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of GlaxoSmithKline?s (GSK) PROMACTA® (eltrombopag) for the treatment ...
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA ... - StreetInsider.com
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of GlaxoSmithKline's (GSK) PROMACTA(R) (eltrombopag) for the treatment ...
None found at this time.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |